BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2020-01-31
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see primarily if BYL719 is safe to be given to patients
in combination with gemcitabine and nab-paclitaxel. Gemcitabine and nab-paclitaxel is an
FDA-approved regimen to treat pancreatic cancer. Secondary goals will be to find out the
effect on tumor of this new drug combination of BYL719, gemcitabine and nab-paclitaxel. In
the first part of the study, different doses of BYL719 will be tested. In the second part of
the study, all patients will be started at the same dose of BYL719.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute